Literature DB >> 22495668

Melanoma in the brain: biology and therapeutic options.

Geoffrey Thomas Gibney1, Peter A Forsyth, Vernon K Sondak.   

Abstract

The development of brain metastases is a frequent occurrence in patients with disseminated melanoma and contributes to a disproportionate degree of morbidity and mortality. The prognosis is markedly reduced once a patient is diagnosed with central nervous system disease. Definitive therapeutic interventions with resection or stereotactic radiosurgery have improved outcomes and become standard approaches in the management of melanoma brain metastases. With the inclusion of whole-brain radiation in these interventions, there has been a reduction in local recurrences, but no improvement in the overall survival. Still, many patients are not candidates for surgery nor radiotherapy nor develop progressive central nervous system disease after definitive therapy. As new immune-based and targeted therapeutic agents are developed for the treatment of metastatic melanoma, understanding their activity in brain metastases is necessary for effective patient management. In this review, we discuss the biology of brain metastases in metastatic melanoma, current treatment approaches with surgery and radiotherapy, and future systemic therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495668     DOI: 10.1097/CMR.0b013e328352dbef

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  12 in total

1.  Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab.

Authors:  Tijana Skrepnik; Srinath Sundararajan; Haiyan Cui; Baldassarre Stea
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

2.  Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib.

Authors:  David A Liebner; Steven A Walston; Robert Cavaliere; Ciaran J Powers; Eric Sauvageau; Norman L Lehman; Hasel Wayne Slone; Meng Xu-Welliver; Fen Xia; Kari L Kendra
Journal:  Melanoma Res       Date:  2014-04       Impact factor: 3.599

3.  Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma.

Authors:  Lukas W Pfannenstiel; Corey McNeilly; Chaomei Xiang; Kai Kang; Claudia Marcella Diaz-Montero; Jennifer S Yu; Brian R Gastman
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

4.  Challenges in the delivery of therapies to melanoma brain metastases.

Authors:  Gautham Gampa; Shruthi Vaidhyanathan; Brynna-Wilken Resman; Karen E Parrish; Svetomir N Markovic; Jann N Sarkaria; William F Elmquist
Journal:  Curr Pharmacol Rep       Date:  2016-11-09

5.  Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.

Authors:  Shruthi Vaidhyanathan; Rajendar K Mittapalli; Jann N Sarkaria; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2014-05-29       Impact factor: 3.922

6.  Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.

Authors:  Shruthi Vaidhyanathan; Brynna Wilken-Resman; Daniel J Ma; Karen E Parrish; Rajendar K Mittapalli; Brett L Carlson; Jann N Sarkaria; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2015-11-24       Impact factor: 4.030

7.  Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.

Authors:  Sarah Sloot; Yian A Chen; Xiuhua Zhao; Jamie L Weber; Jacob J Benedict; James J Mulé; Keiran S Smalley; Jeffrey S Weber; Jonathan S Zager; Peter A Forsyth; Vernon K Sondak; Geoffrey T Gibney
Journal:  Cancer       Date:  2017-10-12       Impact factor: 6.860

Review 8.  Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol.

Authors:  Shearwood McClelland; Tim Lautenschlaeger; Yong Zang; Nasser H Hanna; Kevin Shiue; Aaron P Kamer; Namita Agrawal; Susannah G Ellsworth; Ryan M Rhome; Gordon A Watson
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-23

9.  Stereotactic radiosurgery for brain metastases from malignant melanoma.

Authors:  Sebastian M Christ; Anand Mahadevan; Scott R Floyd; Fred C Lam; Clark C Chen; Eric T Wong; Ekkehard M Kasper
Journal:  Surg Neurol Int       Date:  2015-08-20

10.  High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases.

Authors:  Melinda B Chu; Mark J Fesler; Eric S Armbrecht; Scott W Fosko; Eddy Hsueh; John M Richart
Journal:  Chemother Res Pract       Date:  2013-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.